David Baranano
Ophthalmology · Baltimore, MDNPI 1407992050
Payments from drug & device makers
What this record shows
11 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 49.1% of the total. 2025 is the largest year on record at $2,241, 5.6 times the $400 reported in 2019.
Across 60 payments — averaging $68.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$985
- AbbVie$286
- Genentech USA, Inc.$215
- Genentech, Inc.$211
- Novartis$151
- plus $250 from 5 others
Across 18 payments — averaging $1691.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$30K
What the payments were for
- Travel & lodging$1,79143%
- Food & beverage$2,33357%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 5 | $2,026 |
| Regeneron Healthcare Solutions, Inc. | 21 | $985 |
| AbbVie(2 entities) | 8 | $286 |
| Genentech USA, Inc. | 6 | $215 |
| Genentech, Inc. | 3 | $211 |
| Novartis | 7 | $151 |
| Bausch & Lomb Americas Inc. | 5 | $112 |
| F. Hoffmann-la Roche AG | 1 | $59 |
| Biogen | 2 | $37 |
| Harrow Eye, LLC | 1 | $23 |
| Eyepoint US, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$376
- EYLEA HD$248
- Non-Covered Product$167
- OZURDEX$106
How this compares
$4,124 in reported general payments places this provider in the 75th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 133 | $13,346 |
| Prednisolone Acetate | 149 | $8,844 |
| Ketorolac Tromethamine | 51 | $2,133 |
| Atropine Sulfate | 14 | $830 |
| Timolol Maleate | 26 | $620 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 16 | $338 |
| ErythromycinErythromycin Base | 13 | $130 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Baltimore
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Neil BresslerBaltimore$265K
- Adrienne ScottBaltimore$170K
- Jennifer ThorneBaltimore$128K
- Earl CravenBaltimore$120K
- Peter CampochiaroBaltimore$103K
- Gail SchwartzBaltimore$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.